XNW5004 clinical trials
Also written XNW5004.
How each study uses XNW5004 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the XNW5004 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test XNW5004.
- Jan 2027To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaPhase 2 · Evopoint Biosciences Inc.
- Jul 2027Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerPhase 1/2 · Evopoint Biosciences Inc.
Studies
Open first, then newest update. How each study uses XNW5004 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2Evopoint Biosciences Inc.NCT06702995Written as XNW5004
- Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaRecruitingPhase 1/2Evopoint Biosciences Inc.NCT07730515Written as XNW5004 combined with CHOEP (incremental)
- Study of XNW5004 Tablets in Advanced Prostate CancerNot yet recruitingPhase 2Evopoint Biosciences Inc.NCT07730580Written as XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone
- Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaRecruitingPhase 2Evopoint Biosciences Inc.NCT07545603Written as XNW5004 tablets
- To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruitingPhase 2Evopoint Biosciences Inc.NCT06702605Written as XNW5004 tablets
- To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced TumorsCompletedPhase 1/2Evopoint Biosciences Inc.NCT06558513Written as XNW5004 tablets
- Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedPhase 1/2Evopoint Biosciences Inc.NCT06022757Written as XNW5004